Chakraborty, R., Cliff, E. R. S., & Kishtagari, A. (2023). Assessing the Impact of Blood Cancer Talks, a Novel ‘how I Treat’ Style Podcast on Hematologic Malignancies: A Survey-Based Analysis. Blood, 142(Supplement 1), 7270–7270. https://doi.org/10.1182/blood-2023-184594

Fu, J., Li, S., Liu, G., MA, H., Marcireau, C., Mapara, M., & Lentzsch, S. (2023). Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways. Blood, 142(Supplement 1), 6618–6618. https://doi.org/10.1182/blood-2023-190740

Coombs, C. C., Woyach, J. A., Brown, J. R., Ghia, P., Roeker, L. E., Patel, K., Eyre, T. A., Tam, C. S., Seymour, J. F., Shah, N. N., Flinn, I. W., Cheah, C. Y., Ma, S., Rhodes, J. M., Izutsu, K., Jurczak, W., Wierda, W. G., Loubert, A., Payakachat, N., … Lamanna, N. (2023). Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study. Blood, 142(Supplement 1), 6535–6535. https://doi.org/10.1182/blood-2023-186145

Chernak, B., Galan-Diez, M., Ali, A. M., Cuesta-Dominguez, A., Chen, Z., Koehnke, T., Majeti, R., Carroll, M., Raza, A., & Kousteni, S. (2023). Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 142(Supplement 1), 4118–4118. https://doi.org/10.1182/blood-2023-174485

Defilipp, Z., Kim, H. T., Spyrou, N., Kowalyk, S., Eng, G., Beheshti, R., Baez, J., Ayuk, F. A., Choe, H., Etra, A., Grupp, S., Hexner, E. O., Hogan, W. J., Kitko, C. L., Qayed, M., Reshef, R., Vasova, I., Zeiser, R., Young, R., … Chen, Y.-B. (2023). The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd. Blood, 142(Supplement 1), 3576–3576. https://doi.org/10.1182/blood-2023-182300

Wang, X. K., Uzuni, A., Belay, K., Harle, D. W., Gordillo, C. A., Macedo, R. J., Chakrabarti, S., Shi, L., Pressler, M., Fuller, J., Azizi, E., & Reshef, R. (2023). Characteristics of Alloreactive T-Cell Clones That Predict Early Development of Acute GvHD Following Allogeneic HCT. Blood, 142(Supplement 1), 2042–2042. https://doi.org/10.1182/blood-2023-187932

Biran, N., Dhakal, B., Niesvizky, R., Lentzsch, S., McKay, J. T., Vesole, D. H., Nooka, A. K., Paul, B., Hari, P. N., Stork-Sloots, L., D’Ambrosi, S., Kuiper, R., van Vliet, M., Siegel, D. S., Usmani, S. Z., & van Rhee, F. (2023). Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients. Blood, 142(Supplement 1), 3386–3386. https://doi.org/10.1182/blood-2023-180761

Mohyuddin, G. R., Chakraborty, R., Cliff, E. R. S., & Derman, B. A. (2023). Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. EClinicalMedicine, 65, 102272. https://doi.org/10.1016/j.eclinm.2023.102272

Kim, S., Armand, J., Safonov, A., Zhang, M., Soni, R. K., Schwartz, G., McGuinness, J. E., Hibshoosh, H., Razavi, P., Kim, M., Chandarlapaty, S., & Yang, H. W. (2023). Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Cell Reports, 42(11), 113198. https://doi.org/10.1016/j.celrep.2023.113198

Berger, S., Pini, N., Lucchini, M., Nugent, J. D., Acosta, L., Angal, J., Rauh, V. A., Elliott, A. J., Myers, M. M., Fifer, W. P., & Perzanowski, M. S. (2023). Neonatal rhinorrhea, heart rate variability, and childhood exercise-induced wheeze. Journal of Allergy and Clinical Immunology: Global, 2(4), 100149. https://doi.org/10.1016/j.jacig.2023.100149

Bupathi, M., Wang, J. S., Hu-Lieskovan, S., Piha-Paul, S. A., Chmielowski, B., Garmezy, B., Najjar, Y. G., Stein, M. N., Yao, L., Kanodia, J., Clynes, R., McGovern, P., & Thompson, B. (2023). 764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0764

Stein, M. N., Hawley, J., Zibelman, M., Pachynski, R., Dreicer, R., Zarrabi, K. K., Miles, B., Hauke, R. J., Marshall, M. A., Jones, B., Wheeler, V., Sebastian, S., Anderson, K., Vardeu, A., Davis, C., Bendall, J., & Shore, N. (2023). 665 Immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer: A clinical trial in progress. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0665

Kinslow, C. J., Rae, A. I., Taparra, K., Kumar, P., Siegelin, M. D., Grinband, J., Gill, B. J. A., McKhann, G. M., Sisti, M. B., Bruce, J. N., Canoll, P. D., Iwamoto, F. M., Horowitz, D. P., Kachnic, L. A., Neugut, A. I., Yu, J. B., Cheng, S. K., & Wang, T. J. C. (2023). MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research, 29(21), 4399–4407. https://doi.org/10.1158/1078-0432.ccr-23-1295

Hawley, J. E., Obradovic, A. Z., Dallos, M. C., Lim, E. A., Runcie, K., Ager, C. R., McKiernan, J., Anderson, C. B., Decastro, G. J., Weintraub, J., Virk, R., Lowy, I., Hu, J., Chaimowitz, M. G., Guo, X. V., Zhang, Y., Haffner, M. C., Worley, J., Stein, M. N., … Drake, C. G. (2023). Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell, 41(11), 1972-1988.e5. https://doi.org/10.1016/j.ccell.2023.10.006

Malki, M. A., Keyzner, A., Suh, H. C., Matin, A., Buonomo, E., Wang, Y., Abelowitz, N., Murray, J., MacBeath, G., Barton, D., Chattopadhyay, S., & Reshef, R. (2023). 682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0682

Kearney, A. L., & Vasan, N. (2023). A New Wave of PI3Kα Inhibitors. Cancer Discovery, 13(11), 2313–2315. https://doi.org/10.1158/2159-8290.cd-23-0945

Chakraborty, R., Hillengass, J., & Lentzsch, S. (2023). How do we image patients with multiple myeloma and precursor states? British Journal of Haematology, 203(4), 536–545. Portico. https://doi.org/10.1111/bjh.18880

Alrawabdeh, J., Alzu’bi, M., Alzyoud, M., Odeh, N., Hamadneh, Y., Mian, H., Mohyuddin, G. R., Kelkar, A. H., Goodman, A. M., Chakraborty, R., Russler-Germain, D. A., Mehra, N., Baggio, D., Cliff, E. R. S., & Al Hadidi, S. (2023). Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review. JNCI Cancer Spectrum, 7(6). https://doi.org/10.1093/jncics/pkad100

Tam, C. S., Lamanna, N., O’Brien, S. M., Qiu, L., Yang, K., Barnes, G., Wu, K., Salmi, T., & Brown, J. R. (2023). Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial. Current Medical Research and Opinion, 39(11), 1497–1503. https://doi.org/10.1080/03007995.2023.2262378

Mapanga, W., Ayeni, O. A., Chen, W. C., Jacobson, J. S., Neugut, A. I., Ruff, P., Cubasch, H., O’Neil, D. S., Buccimazza, I., Čačala, S., Stopforth, L. W., Farrow, H. A., Nietz, S., Phakathi, B., Chirwa, T., McCormack, V. A., & Joffe, M. (2023). The South African breast cancer and HIV outcomes study: Profiling the cancer centres and cohort characteristics, diagnostic pathways, and treatment approaches. PLOS Global Public Health, 3(10), e0002432. https://doi.org/10.1371/journal.pgph.0002432

Kasbekar, M., Mitchell, C. A., Proven, M. A., & Passegué, E. (2023). Hematopoietic stem cells through the ages: A lifetime of adaptation to organismal demands. Cell Stem Cell, 30(11), 1403–1420. https://doi.org/10.1016/j.stem.2023.09.013

Nagaraj, G., Vinayak, S., Khaki, A. R., Sun, T., Kuderer, N. M., Aboulafia, D. M., Acoba, J. D., Awosika, J., Bakouny, Z., Balmaceda, N. B., Bao, T., Bashir, B., Berg, S., Bilen, M. A., Bindal, P., Blau, S., Bodin, B. E., Borno, H. T., … Castellano, C. (2023). Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study. ELife, 12. CLOCKSS. https://doi.org/10.7554/elife.82618

Kentros, P. A., Huang, Y., Wylie, B. J., Khoury‐Collado, F., Hou, J. Y., de Meritens, A. B., St. Clair, C. M., Hershman, D. L., & Wright, J. D. (2023). Ambient particulate matter air pollution exposure and ovarian cancer incidence in the USA: An ecological study. BJOG: An International Journal of Obstetrics & Gynaecology, 131(5), 690–698. Portico. https://doi.org/10.1111/1471-0528.17689

Zeng, Y., Arisa, O., Peer, C. J., Fojo, A., & Figg, W. D. (2024). PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics. Seminars in Oncology, 51(1–2), 19–24. https://doi.org/10.1053/j.seminoncol.2023.09.005

Jain, M. D., Miklos, D. B., Jacobson, C. A., Timmerman, J. M., Sun, J., Nater, J., Fang, X., Patel, A., Davis, M., Heeke, D., Trinh, T., Mattie, M., Neumann, F., Kim, J. J., To, C., Filosto, S., & Reshef, R. (2023). Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11. Clinical Cancer Research, 29(20), 4118–4127. https://doi.org/10.1158/1078-0432.ccr-23-0916

Lydeard, J. R., Lin, M. I., Ge, H. G., Halfond, A., Wang, S., Jones, M. B., Etchin, J., Angelini, G., Xavier-Ferrucio, J., Lisle, J., Salvadore, K., Keschner, Y., Mager, H., Scherer, J., Hu, J., Mukherjee, S., & Chakraborty, T. (2023). Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity. Molecular Therapy - Methods & Clinical Development, 31, 101135. https://doi.org/10.1016/j.omtm.2023.101135

Soni, M. K., Migliori, E., Fu, J., Assal, A., Chan, H. T., Pan, J., Khatiwada, P., Ciubotariu, R., May, M. S., Pereira, M. R., De Giorgi, V., Sykes, M., Mapara, M. Y., & Muranski, P. J. (2023). The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1212203

Safari, M., Scotto, L., Litman, T., Petrukhin, L. A., Zhu, H., Shen, M., Robey, R. W., Hall, M. D., Fojo, T., & Bates, S. E. (2023). Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms. Cancers, 15(20), 4960. https://doi.org/10.3390/cancers15204960

Tran, L. M., Macedo, C., Zahorchak, A. F., Gu, X., Elinoff, B., Singhi, A. D., Isett, B., Zeevi, A., Sykes, M., Breen, K., Srivastava, A., Ables, E. M., Landsittel, D., Styn, M. A., Humar, A., Lakkis, F. G., Metes, D. M., & Thomson, A. W. (2023). Donor-derived regulatory dendritic cell infusion modulates effector CD8 + T cell and NK cell responses after liver transplantation. Science Translational Medicine, 15(717). https://doi.org/10.1126/scitranslmed.adf4287

Ruan, J., Zain, J., Palmer, B., Jovanovic, B., Mi, X., Swaroop, A., Winter, J. N., Gordon, L. I., Karmali, R., Moreira, J., Petrich, A. M., & Pro, B. (2023). Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Advances, 7(19), 5771–5779. https://doi.org/10.1182/bloodadvances.2023009767

Wei, A. Z., Chen, L. N., Orloff, M., Ariyan, C. E., Asgari, M., Barker, C. A., Buchbinder, E., Chandra, S., Couts, K., Frumovitz, M. M., Futreal, A., Gershenwald, J. E., Hanna, E. Y., Izar, B., LeBlanc, A. K., Leitao, M. M., Lipson, E. J., Liu, D., McCarter, M., … Carvajal, R. D. (2023). Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA). Pigment Cell & Melanoma Research, 36(6), 542–556. Portico. https://doi.org/10.1111/pcmr.13139

Patel, R., Negassa, A., Tolu, S. S., Acuna-Villaorduna, A., & Goel, S. (2024). Effectiveness of Biologic Agents Among Hispanic Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 23(1), 14-21.e1. https://doi.org/10.1016/j.clcc.2023.10.001

Cochran, S. J., Acosta, L., Divjan, A., Lemons, A. R., Rundle, A. G., Miller, R. L., Sobek, E., Green, B. J., Perzanowski, M. S., & Dannemiller, K. C. (2023). Fungal diversity in homes and asthma morbidity among school-age children in New York City. Environmental Research, 239, 117296. https://doi.org/10.1016/j.envres.2023.117296

O’Neil, D. S., Ayeni, O. A., Farrow, H. A., Chen, W. C., Demetriou, G., Buccimazza, I., Čačala, S., Stopforth, L. W., Joffe, M., Antoni, M. H., Lopes, G., Pumpalova, Y. S., Mapanga, W., Jacobson, J. S., Crew, K. D., Neugut, A. I., Ruff, P., & Cubasch, H. (2023). The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast Cancer. The Oncologist, 28(10), e921–e929. https://doi.org/10.1093/oncolo/oyad056

Chakraborty, R., Milani, P., Palladini, G., & Gertz, M. (2023). Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies. The Lancet Haematology, 10(11), e936–e940. https://doi.org/10.1016/s2352-3026(23)00175-8

Dacic, S., Travis, W., Redman, M., Saqi, A., Cooper, W. A., Borczuk, A., Chung, J.-H., Glass, C., Lopez, J. M., Roden, A. C., Sholl, L., Weissferdt, A., Posadas, J., Walker, A., Zhu, H., Wijeratne, M. T., Connolly, C., Wynes, M., Bota-Rabassedas, N., … Wistuba, I. (2023). International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. Journal of Thoracic Oncology, 18(10), 1290–1302. https://doi.org/10.1016/j.jtho.2023.07.017

Basu, A., Umashankar, S., Musthafa, M., Jones, T., Blevins, K., Brown, T., Heditsian, D., Parker, B., Brain, S., Simmons, C., Hieken, T. J., Ruddy, K., Mainor, C., Tevis, S., Blaes, A., Rugo, H. S., Dunn, I., Melisko, M., Esserman, L., & Hershman, D. L. (2023). 374P Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial. Annals of Oncology, 34, S332–S333. https://doi.org/10.1016/j.annonc.2023.09.552

LaRose, M., Zhou, M., Lu, S., Wei, H., Bates, S. E., Schwartz, L., & Fojo, A. T. (2023). 1328P Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib. Annals of Oncology, 34, S766–S767. https://doi.org/10.1016/j.annonc.2023.09.2361

Unger, J. M., Xiao, H., Vaidya, R., LeBlanc, M., & Hershman, D. L. (2023). Medicaid Expansion of the Patient Protection and Affordable Care Act and Participation of Patients With Medicaid in Cancer Clinical Trials. JAMA Oncology, 9(10), 1371. https://doi.org/10.1001/jamaoncol.2023.2800

Wilky, B., Trent, J. C., Gordon, M., El-Khoueiry, A. B., Bullock, A., Henick, B. S., Schwartz, G. K., Agulnik, M., Mahadevan, D., Patel, J., Grossman, J., Rosenthal, K., O’Day, S. J., & Tsimberidou, A. M. (2023). 1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma. Annals of Oncology, 34, S1032–S1033. https://doi.org/10.1016/j.annonc.2023.09.1148

Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., Luke, J. J., Mitchell, T. C., Mooradian, M. J., Rubin, K. M., Salama, A. K., Shirai, K., Taube, J. M., Tawbi, H. A., Tolley, J. K., … Sullivan, R. J. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal for ImmunoTherapy of Cancer, 11(10), e006947. https://doi.org/10.1136/jitc-2023-006947

Van Tine, B. A., Ingham, M. A., Attia, S., Meyer, C. F., Baird, J. D., D’Silva, D., O’Keefe, K., Kong, R., Maliakal, P., Gao, L., & Schwartz, G. K. (2023). 1934P Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma. Annals of Oncology, 34, S1039. https://doi.org/10.1016/j.annonc.2023.09.1163

Ma, Y., Mukherjee, S., & Ma, J. (2023). Call for Special Issue Papers: The “Yin-Yang” Activities of Tumor-Induced Inflammatory Cytokines for Cancer Immunotherapy, Detection and Prognosis. Journal of Interferon & Cytokine Research, 43(10), 439–440. https://doi.org/10.1089/jir.2023.29056.cfp

Fathi, F., Suek, N., Parks, C., & Sykes, M. (2023). 312.1: Defining the human anti-pig xenoreactive T cell repertoire. Transplantation, 107(10S2), 94–94. https://doi.org/10.1097/01.tp.0000994288.59179.b7

Lamanna, N., Tam, C., Jurczak, W., Kontos, A., Konig, H., Ruppert, A., Tsai, D., & Scheliga, A. (2023). COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS. Hematology, Transfusion and Cell Therapy, 45, S161. https://doi.org/10.1016/j.htct.2023.09.359

Orloff, M., Watkins, C., Carvajal, R. D., Shoushtari, A. N., Sacco, J. J., Schlaak, M., Gama, J., & Butler, M. O. (2023). 1129P Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up. Annals of Oncology, 34, S678. https://doi.org/10.1016/j.annonc.2023.09.2263

Drobner, J., Portal, D., Runcie, K., Yang, Y., & Singer, E. A. (2023). Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy. Journal of Kidney Cancer and VHL, 10(3), 37–60. https://doi.org/10.15586/jkcvhl.v10i3.295

Qunaj, L., May, M. S., Neugut, A. I., & Herzberg, B. O. (2023). Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1252516

Mishkin, A. D., Allen, N. C., Cheung, S. G., Faccini, M. C., Flicker, L. S., & Shalev, D. (2023). The Stresses of Surrogate Decision-Making: Contributing Factors and Clinicians’ Role in Mitigation. American Journal of Hospice and Palliative Medicine®, 41(8), 895–905. https://doi.org/10.1177/10499091231198750

Al Malki, M. M., London, K., Baez, J., Akahoshi, Y., Hogan, W. J., Etra, A., Choe, H., Hexner, E., Langston, A., Abhyankar, S., Ponce, D. M., DeFilipp, Z., Kitko, C. L., Adekola, K., Reshef, R., Ayuk, F., Capellini, A., Chanswangphuwana, C., Eder, M., … Levine, J. E. (2023). Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease. Blood Advances, 7(17), 5189–5198. https://doi.org/10.1182/bloodadvances.2023009853